ReVance Therapeutics Secures $25,620,000 Series D Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e9e79dac-682b-48a9-8e3a-ede6364c5504&Preview=1 -
Date
12/28/2009 -
Company Name
ReVance Therapeutics -
Mailing Address
7555 Gateway Boulevard Newark, CA 94560 -
Company Description
Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis. -
Website
http://www.revance.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,620,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Undisclosed
